Supernus Pharmaceuticals Inc
SUPN
ISIN null / Valor 18393960
Supernus Pharmaceuticals Inc
UMushroom community rating:
About company
Supernus Pharmaceuticals is a U.S.-based specialty pharmaceutical company (NASDAQ: SUPN) that researches, develops, licenses and commercializes branded prescription therapies for central nervous system disorders, particularly in neurology and psychiatry. Its commercial portfolio has included extended‑release antiseizure medicines and, more recently, Qelbree (viloxazine), a non‑stimulant treatment for attention‑deficit/hyperactivity disorder; the company also pursues development-stage candidates, formulation technologies and in‑licensing or partnership arrangements to expand its pipeline and product reach. Supernus generates revenue primarily from sales of its marketed products in the U.S. and from collaboration agreements, while investing in clinical programs aimed at expanding indications and developing new CNS therapies.
Summarized from source with an LLMView SourceSector: HealthcareKey figures
Performance
Volatility
2594 M
Market cap (USD)
460,502
Daily traded volume (Shares)
37.28 / 36.11
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
